At least two of the most promising approaches–the CD19/CD3 bi-specific T-cell engager, blinatumomab, and the CD19-chimeric antigen receptor T (CAR-T) cell therapy–engage the patient's own T cells to bind and lyse the CD19+ B-ALL cells. Here, CD19 is linked to acute lymphoblastic leukemia.